sur HBM Healthcare Investments AG (ETR:CH001262)
Lycia Therapeutics Raises USD 317.5 Million in Nasdaq Debut
HBM Healthcare Investments announced the IPO success of Lycia Therapeutics, its portfolio company. The biotechnology firm, focused on degrading extracellular proteins to treat autoimmune and allergic diseases, raised USD 317.5 million by pricing its offering at USD 18 per share. The shares began trading on Nasdaq on October 23, 2026, under LYCA, closing at USD 30 on the first day, a 66.7% gain from the IPO price.
HBM invested a total of USD 13.5 million in Lycia, acquiring a 2.2% stake now valued at USD 36.8 million. Lycia's advancements are rooted in its LYTAC platform, with leading candidates targeting food allergies and Graves' disease. The company's foundation is linked to Nobel laureate Carolyn Bertozzi's work.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de HBM Healthcare Investments AG